University of Utah
Salt Lake City, Utah, 84112, United States
NCT Number: NCT04015908
The primary objective of this trial is to determine whether the combination of three non-opioid analgesics (multimodal analgesia) can significantly reduce or eliminate the need for opioids after ambulatory surgery.
A secondary objective would be to present credible data for insurance providers about the opioid sparing effect of these medications. This data may encourage insurance providers to support payment for short term use of certain analgesics that currently require prior authorization.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
Salt Lake City, Utah, 84112, United States
Prescription opioids are associated with addiction and accidental overdose, yet they continue to be the most commonly prescribed analgesics after ambulatory surgery.
Multimodal analgesia is a promising alternative to opioids. It is based on the theory that a combination of more than one analgesic (with non-opioid mechanisms of action) can provide pain relief equal to or exceeding that of traditional opioids.
Multimodal analgesia is not associated with opioid related side effects such as respiratory depression, nausea, constipation, and itching.
Implementation of multi-modal analgesia in an ambulatory setting is challenging for a number of reasons.
First, patient compliance with multiple medications and complex dosing schedules is poor.
Second, misinformation still exists about the dosing of acetaminophen and NSAIDS (non-steroidal anti-inflammatory drugs). For example, many patients and health care providers believe that acetaminophen and NSAIDS cannot be taken concurrently. As a result, the additive analgesic effect of combining these drugs is not achieved.
Finally, some medications used for multimodal analgesia can be difficult to procure in the ambulatory setting. For example, pregabalin (trade name Lyrica) has been used successfully to treat acute pain and reduce opioid requirements after surgery. However, its mechanism of action is similar to that of gabapentin (an older and less expensive drug) and insurers are reluctant to approve its use over the expensive alternative.
Although gabapentin is a useful analgesic for chronic pain, its delayed onset of activity and unpredictable blood levels after oral administration make it impractical to use in the setting of acute pain. In fact, optimal dosing of gabapentin may require several days or weeks to establish.By contrast, pregabalin has a rapid onset of action with consistent and predictable plasma levels after oral administration.
For this trial, patients in the control group would receive traditional postoperative pain medication consisting of a combination of oxycodone and acetaminophen (trade name Percocet) as needed at 4-6 hour intervals.
Patients in the study group would receive the following:
The principles of postoperative pain management addressed in this protocol are supported by existing literature.
The primary objective of this trial is to determine whether the combination of three non-opioid analgesics (multimodal analgesia) can significantly reduce or eliminate the need for opioids after ambulatory surgery.
A secondary objective would be to present credible data for insurance providers about the opioid sparing effect of these medications. This data may encourage insurance providers to support payment for short term use of certain analgesics that currently require prior authorization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Celecoxib 100mg
Other names: Celebrex
Acetaminophen 325mg
Other names: Paracetamol
Pregabalin 50 mg
Other names: Lyrica
oxycodone 5-10 mg
Other names: Xtampza ER, Oxaydo, Roxicodone
Percocet (oxycodone 5mg/acetaminophen 325 mg)
Other names: Oxycodone / Paracetamol
Time frame: Cumulative every day after 6 days post-operative
Pain as measured by a 0-10 Visual Analog Scale (VAS) pain scale, where "0" is the lowest score and "10" is the highest score. For example, 10 would be severe pain and 0 would be none. Cumulative scores were the total scores over 6 days and were expressed with the absolute totals with range. No subscales were used. Cumulative scores represent the absolute sum of each data point for 6 days. The total cumulative range for pain is 0-60.
Time frame: Cumulative every day after 6 days post-operative
Nausea as measured by a 0-10 Visual Analog Scale (VAS) nausea scale, where "0" is the lowest score and "10" is the highest score. For example, 10 would be severe nausea and 0 would be none. Cumulative scores were the total scores over 6 days and were expressed with the absolute totals with range. No subscales were used. Cumulative scores represent the absolute sum of each data point for 6 days. The total cumulative range for nausea is 0-60.
Time frame: Cumulative every day after 6 days post-operative
Itching as measured by a 0-10 Visual Analog Scale (VAS) itching scale, where "0" is the lowest score and "10" is the highest score. For example, 10 would be severe itching and 0 would be none. Cumulative scores were the total scores over 6 days and were expressed with the absolute totals with range. No subscales were used. Cumulative scores represent the absolute sum of each data point for 6 days. The total cumulative range for itching is 0-60.
Time frame: Cumulative every day after 6 days post-operative
Oxycodone use, measured by number of 5-mg tablets as standard dose
University of Utah
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03629197
Chronic Pain, Communication Research
Sacramento, California, United States
View Trial DetailsNCT05506878
Abdominal Pain, Agnosia
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT04873401
COVID-19, Chemically-Induced Disorders
New York, United States
View Trial DetailsNCT05351905
Cannabis, Chemically-Induced Disorders
Toronto, Ontario, Canada
View Trial Details